Research programme: antimalarials - Bayer/Medicines for Malaria VentureAlternative Names: Artemisone
Latest Information Update: 08 Nov 2006
At a glance
- Originator Bayer; Medicines for Malaria Venture
- Developer Bayer
- Class Antimalarials
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Malaria
Most Recent Events
- 08 Nov 2006 Discontinued - Preclinical for Malaria treatment in Germany (unspecified route)
- 08 May 2002 Preclinical trials in Malaria treatment in Germany (unspecified route)